He says he doesn't need to lose weight and started low doses for longevity, but wonders if it's too early to know benefits or long-term side effects.
Recap by typeshit. Post by Travis Kimball on X.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
Houman takes on a question he says many men on Ozempic, Wegovy and Mounjaro ask him. The clip pushes a comment-for-guide offer.
Day one sessions covered prediabetes, the newest GLP-1 receptor agonists, tirzepatide and bariatric care, per the organizers' recap.
Loading…